title: Maintenance therapy with monoclonal antibodies in metastatic HER2-positive breast cancer: A review of studies
metadata.name: dc.contributor.author
metadata.value: Chistyakova, Elenа A.
metadata.lang: -
metadata.name: dc.contributor.author
metadata.value: Orlova, Rashida V.
metadata.lang: -
metadata.name: dc.date.accessioned
metadata.value: 2023-08-17T17:08:05Z
metadata.lang: -
metadata.name: dc.date.available
metadata.value: 2023-08-17T17:08:05Z
metadata.lang: -
metadata.name: dc.date.issued
metadata.value: 2023-03
metadata.lang: -
metadata.name: dc.identifier.citation
metadata.value: Chistyakova E. A., Orlovа R. V. Maintenance therapy with monoclonal antibodies in metastatic HER2-positive breast cancer: A review of studies. Vestnik of Saint Petersburg University. Medicine, 2023, vol. 18, issue 1, pp. 63–69. https://doi.org/10.21638/spbu11.2023.105 (In Russian)
metadata.lang: en_GB
metadata.name: dc.identifier.other
metadata.value: https://doi.org/10.21638/spbu11.2023.105
metadata.lang: -
metadata.name: dc.identifier.uri
metadata.value: http://hdl.handle.net/11701/43764
metadata.lang: -
metadata.name: dc.description.abstract
metadata.value: Maintenance therapy is a medical treatment after achieving stabilization, partial or complete
  response by the first line therapy of a metastatic malignant tumor. The goals of such treatment
  are to maintain the effect of the first line therapy, to increase progression-free survival,
  and, in some cases, overall survival. Targeted monoclonal antibody therapy is a maintenance
  treatment option widely used in clinical practice for metastatic HER2-positive breast cancer,
  but it remains one of the least studied. This analysis of available world studies was carried
  out in order to form an idea about the possibilities of maintenance therapy and promising
  areas for studying this topic. The article presents an up-to-date and complete review of data
  on metastatic HER2-positive breast cancer maintenance therapy with various drugs from the
  monoclonal antibody group, as well as cases of discontinuation of maintenance therapy due to
  high toxicity or at the request of the patient. Besides, authors analyzed the treatment options
  of maintenance therapy in patients with luminal HER2-positive breast cancer and the possibilities
  of intensifying monoclonal antibody maintenance therapy by antihormonal drugs for
  this group of patients.
metadata.lang: en_GB
metadata.name: dc.language.iso
metadata.value: ru
metadata.lang: en_GB
metadata.name: dc.publisher
metadata.value: St Petersburg State University
metadata.lang: en_GB
metadata.name: dc.relation.ispartofseries
metadata.value: Vestnik of St Petersburg University. Medicine;Volume 18; Issue 1
metadata.lang: -
metadata.name: dc.subject
metadata.value: maintenance therapy
metadata.lang: en_GB
metadata.name: dc.subject
metadata.value: metastatic breast cancer
metadata.lang: en_GB
metadata.name: dc.subject
metadata.value: trastuzumab
metadata.lang: en_GB
metadata.name: dc.subject
metadata.value: pertuzumab
metadata.lang: en_GB
metadata.name: dc.title
metadata.value: Maintenance therapy with monoclonal antibodies in metastatic HER2-positive breast cancer: A review of studies
metadata.lang: en_GB
metadata.name: dc.type
metadata.value: Article
metadata.lang: en_GB
resources.filename: 05.pdf
resources.url: https://dspace.spbu.ru/bitstream/11701/43764/1/05.pdf
resources.format: Adobe PDF
resources.size: 597,78 kB